KYLYS
BIOMOLECULES NOW, FOR YOUR FUTURE
BIOMOLECULES NOW, FOR YOUR FUTURE
KYLYS is a Life Science Spin-off from the University of Geneva, dedicated to advancing into clinical development. Their focus on science and biotechnology drives their ambition to pioneer a unique technology for highly effective and safe products utilizing the next generation of hyaluronic acid (HA). The company's offerings span across aesthetic and medical realms, under KYLYS Aesthetics and KYLYS respectively. KYLYS is positioned to disrupt the HA delivery landscape within various fields including aesthetic, rheumatology, reconstructive surgery, drug delivery system, and even veterinary applications. Founded in 2017 and headquartered in Switzerland, the latest injection of funds amounting to Fr.100.00K came in the form of Debt Financing from FONGIT on 16 May 2023. This recent investment signals confidence from a notable investor, accelerating KYLYS's trajectory towards groundbreaking advancements in biotechnology and the pharmaceutical industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | Fr.100.00K | 1 |
|
16 May 2023 |
| Seed Round | Unknown | 1 |
|
01 Jan 2018 |
No recent news or press coverage available for KYLYS.
We care about your data, and we'd love to use cookies make your experience better.
